NEWS・COLUMN
We send the latest information from SMC Laboratories.
STAM™ mice study: demonstration of MSCs-based cell therapy study for the NASH treatment
We introduce an example of a drug evaluation study on the efficacy of cell therapy in the treatment of NASH using our STAM™ mice, model of non-alcoholic steatohepatitis (NASH). Title: Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model ( Najimi et al., Cells. 2022 ) Article…
Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice
SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-clinical services with the STAM™ mice in Cells. Title: Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma (Rajan PK et al., Cells. 2023) Article Link ► [DOI: 10.3390/cells12192367] In this…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD Day was established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness, share knowledge, and discuss ways to reduce the burden of COPD worldwide. GOLD is a global organization promoting…
【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice
We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studies of IL-18 inhibitor using our DDC-induced primary sclerosing cholangitis (PSC) mouse model in the journal Biomed Pharmacother. Title: Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease (Kim DH et al., Biomed…
SMC will present study at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting
We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting to be held in Boston, MA on November 10-14, 2023. Our abstract for this presentation has been published in Hepatology (October 2023 – Volume 78 – Abstracts Supplement S1). 2348-C…
SMC will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023)
We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023) from November 2th (Thu) to 5th (Sun). JDDW 2023 will be host to the 65th Annual Meeting of the Japanese Society of Gastroenterology, the 105th Congress of the Japan Gastroenterological Endoscopy Society, the 27th General…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in liver cirrhosis due to NASH/MASH For detailed information, see the below URL. Press Release Galectin Therapeutics Reports the Positive Outcome of the…
Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre-clinical services with the STAM™ mice in Biomed Pharmacother. Title: GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling (Lee SH et al., Biomed Pharmacother., 2023) Article…
Exciting News from 89bio, Inc.! U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in NASH
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new drug candidate for non-alcoholic steatohepatitis (NASH). The BTD is designed to expedite the development and review for new drug candidates and recognized by the U.S. FDA as promising for the treatment of serious or fatal diseases for which no…
SMC at BioJapan 2023 in October!
We are pleased to announce that SMC Laboratories will be attending the BioJapan 2023 from October 11th (Wed) to 13th (Fri). BioJapan is Asia’s largest partnering event and offers attendees the opportunity to partake in many different exhibitions, seminars, and partnering programs, as well as hold face-to-face meetings at on-site exhibition booths. We would like…
SMC attend The Digital Partnering in BioPharm America!
We are pleased to announce that SMC Laboratories will be attending the BioPharm America Partnering Event from September 19th (Tue) to 20th (Wed). So, you can conduct web meeting using partneringONE® platform. If you are attending the event and are interested in our services or STAMTM mice, please feel free to contact us. We look…
Acute Liver Failure Mouse Model Lineup
Acute liver failure (ALF) carries a high mortality of approximately 40%, which is caused by virus infections (hepatitis A, B and E), drug-induced liver injury (acetaminophen/paracetamol) or autoimmune hepatitis. ALF exhibits symptoms of severe injury such as destruction of hepatocytes or decrease in liver function due to massive necrosis and inflammation. We have lineup…